BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bristol-Myers Squibb readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Bristol-Myers Squibb's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06118333-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy 
 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NP
 C01)\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06118333
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585787-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 585787)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate KarXT as a Treatment for Psychosis As
 sociated With Alzheimer's Disease (ADEPT-4)\nEstimated primary completion:
  24 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xa
 nomeline-trospium-chloride#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06585787
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3025@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05803018-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 1/2 readout est. (NCT05803018)
DESCRIPTION:Izalontamab brengitecan\, phase 1/2.\nStudy: A Study of BL-B01D
 1 in Patients With Multiple Solid Tumors\, Including Recurrent or Metastat
 ic Gynecological Malignancies\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05803018
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785039-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05785039)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 in Patients With Multiple Solid Tumors\, Including Locally Advanced or Met
 astatic Urinary System Tumors\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05785039
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05924841-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05924841)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell
  Lung Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05924841
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally 
 Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcino
 ma and Other Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 56587
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05965856-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05965856)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanc
 ed or Metastatic Urothelial Carcinoma and Other Solid Tumors\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05965856
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990803-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05990803)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Ce
 rvical Cancer and Other Gynecological Malignancies\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05990803
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006169-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06006169)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic He
 ad and Neck Squamous Cell Carcinoma and Other Solid Tumors\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06006169
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008054-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06008054)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of SI-B003\,
  BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With L
 ocally Advanced or Metastatic Esophageal Cancer\, Gastric Cancer\, Colorec
 tal Cancer and Other Gastrointestinal Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06008054
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042894-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06042894)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With U
 nresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast 
 Cancer\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06042894
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405425-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06405425)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metasta
 tic Urothelial Carcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0640
 5425
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06437509-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06437509)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung 
 Cancer\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06437509
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471205-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06471205)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or
  Recurrent Metastatic Triple-negative Breast Cancer\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06471205
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06382129)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unrese
 ctable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung C
 ancer(PANKU-Lung02)\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500026-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06500026)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study Comparing BL
 -B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PA
 NKU-Lung03)\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06500026
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477576-9190@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 3 readout est. (NCT05477576)
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 3.\nStudy: Study of RYZ1
 01 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET
  That Has Progressed Following 177Lu-SSA Therapy\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 actinium-225ac-oxodotreotide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05477576
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757869-11184@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:Milvexian: Phase 3 readout est. (NCT05757869)
DESCRIPTION:Milvexian\, phase 3.\nStudy: A Study of Milvexian Versus Apixab
 an in Participants With Atrial Fibrillation\nEstimated primary completion:
  8 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mil
 vexian#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05757869
URL:https://assetmemo.bio/drug/milvexian#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126224-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261210
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 126224)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Assess Efficacy and Safety of KarXT for the Tr
 eatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)\nEstima
 ted primary completion: 9 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06126224
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06122779-597@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Delocamten: Phase 2 readout est. (NCT06122779)
DESCRIPTION:Delocamten\, phase 2\, Heart Failure.\nStudy: Study to Evaluate
  Safety\, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participan
 ts With Heart Failure With Preserved Ejection Fraction (HFpEF)\nEstimated 
 primary completion: 14 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/delocamten#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06122779
URL:https://assetmemo.bio/drug/delocamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268886-688@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Moponetug: Phase 2 readout est. (NCT06268886)
DESCRIPTION:Moponetug\, phase 2\, Alzheimer's Disease.\nStudy: Study to Eva
 luate the Efficacy\, Safety\, and Tolerability of an Anti-MTBR Tau Monoclo
 nal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease\n
 Estimated primary completion: 17 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/moponetug#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06268886
URL:https://assetmemo.bio/drug/moponetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05879055-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pumitamig: Phase 2 readout est. (NCT05879055)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Study of PM8002 in Combination W
 ith Chemotherapy in Patients With NEN\nEstimated primary completion: 1 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 9055
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3025@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Mezigdomide: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Mezigdomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalido
 mide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or
  Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 19085
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinatio
 n With Intravenous Ipilimumab and Chemotherapy in Participants With Previo
 usly Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140836-2264@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib: Phase 3 readout est. (NCT06140836)
DESCRIPTION:Repotrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Repotrectinib Versus Crizotinib in Participants With Locally Adv
 anced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive N
 on-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nEstimated primary completio
 n: 16 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 repotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06140836
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants 
 With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-11182@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: A Safety and Preliminary Effic
 acy Study of CC-99282\, Alone and in Combination With Anti-lymphoma Agents
  in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NH
 L)\nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133750-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07133750)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: PM8002 (BNT327) in Combination Wit
 h Chemotherapy in Patients With Metastatic Colorectal Cancer\nEstimated pr
 imary completion: May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07133750
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962787-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06962787)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal C
 ancer\nEstimated primary completion: May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06962787
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978114-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06978114)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Biliary Tract Cancer.\nStud
 y: A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Adv
 anced Biliary Tract Cancer\nEstimated primary completion: May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0697811
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986785-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06986785)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 Monotherapy\, BL-B01D1 in Combination With Lenvatinib\, BL-B01D1 in Combin
 ation With PD-1 Monoclonal Antibody\, and BL-B01D1 in Combination With PD-
 1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocell
 ular Carcinoma\nEstimated primary completion: May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06986785
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Ce
 rvical Cancer and Endometrial Cancer\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-breng
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07054567
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616532-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06616532)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: PM8002 in
  Combination With Paclitaxel Compared With Chemotherapy as Second-line Tre
 atment in Small Cell Lung Cancer\nEstimated primary completion: May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06616532
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782490-11183@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT06782490)
DESCRIPTION:Irafamdastat\, phase 2\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy\, Safety and Tolerability of BMS-986368 in Particip
 ants With Multiple Sclerosis Spasticity\nEstimated primary completion: 26 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/irafamdasta
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 782490
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-3025@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Schedule\, and Evaluate the Safety and 
 Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Par
 ticipants With Relapsed and/or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06988488
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449209-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06449209)
DESCRIPTION:Pumitamig\, phase 2\, Small Cell Lung Cancer.\nStudy: Safety\, 
 Preliminary Effectiveness of BNT327\, an Investigational Therapy for Patie
 nts With Small-cell Lung Cancer in Combination With Chemotherapy\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06449209
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498986-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06498986)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tabl
 ets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca
 ncer\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06498986
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787664-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06787664)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 in Patients With Locally Advanced or Metastatic Chordoma\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06787664
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06437522-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06437522)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and
  Neck Squamous Cell Carcinoma and Other Solid Tumors\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 izalontamab-brengitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06437522
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06475300)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Ca
 rcinoma and Other Solid Tumors\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 475300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857175-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06857175)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in P
 atients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
 \nEstimated primary completion: June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06857175
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994195-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06994195)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in 
 Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU
 -GYN01)\nEstimated primary completion: June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06994195
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 140913)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Evaluate the Efficacy and Safety of Adjunctive Ka
 rXT for the Treatment of Mania\, With or Without Mixed Features\, in Parti
 cipants With Bipolar-I Disorder Taking Lithium\, Valproate\, or Lamotrigin
 e\nEstimated primary completion: 28 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07140913
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05880706-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05880706)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib 
 Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small
  Cell Lung Cancer\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05880706
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419621-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06419621)
DESCRIPTION:Pumitamig\, phase 3.\nStudy: PM8002 or Placebo Plus Nab-Paclita
 xel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06419621
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356129-11182@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06356129)
DESCRIPTION:Golcadomide\, phase 3\, Large B-Cell Lymphoma.\nStudy: Study to
  Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placeb
 o Plus R-CHOP in Participants With Previously Untreated High-risk Large B-
 cell Lymphoma\nEstimated primary completion: 9 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06356129
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Nivolumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study t
 o Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fix
 ed Dose Combination) in Combination With Carboplatin Plus Etoposide to Tha
 t of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in
  Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).\nEstima
 ted primary completion: 17 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06646276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210723-596@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Danicamtiv: Phase 2/3 readout est. (NCT07210723)
DESCRIPTION:Danicamtiv\, phase 2/3.\nStudy: A Study of the Efficacy and Saf
 ety of Danicamtiv in Participants With Symptomatic Genetic and Familial Di
 lated Cardiomyopathy\nEstimated primary completion: September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07210723
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980949-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270907
DTEND;VALUE=DATE:20270908
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT05
 980949)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: Open-Label Extension Study to Assess the Long-Term Safety
  and Tolerability of KarXT in Subjects With Psychosis Associated With Alzh
 eimer's Disease (ADEPT-3)\nEstimated primary completion: 7 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-
 chloride#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05980949
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-11182@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: A Study to Assess BMS-986458 A
 lone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory N
 on-Hodgkin Lymphomas\nEstimated primary completion: 28 October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06090539
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147348-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07147348)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A First-in-human\, Dose Escalati
 on and Indication Expansion Study of BNT3212 as Monotherapy or in Combinat
 ion With BNT327 in Adults With Advanced Solid Tumors\nEstimated primary co
 mpletion: November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07147348
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-3209@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT04975997)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ope
 n-label Study Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd
 ) Versus Daratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participant
 s With Relapsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary c
 ompletion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06808984-11183@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT06808984)
DESCRIPTION:Irafamdastat\, phase 2.\nStudy: Study to Evaluate the Efficacy\
 , Safety\, and Tolerability of BMS-986368\, for the Treatment of Agitation
  in Participants With Alzheimer's Disease\nEstimated primary completion: 2
 6 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iraf
 amdastat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06808984
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255404-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07255404)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Clinical Trial Testing the Safet
 y of Pumitamig (an Investigational Drug) and How Well it Works When Combin
 ed With Chemotherapy for People Who Have Not Been Treated Yet for Pancreat
 ic Cancer\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07255404
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3132@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3123@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in A
 dult Participants With Relapsed or Refractory and Lenalidomide-exposed Mul
 tiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0661
 5479
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study (
 ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297212-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07297212)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: A Clinical Trial Testing the Safet
 y of the Investigational Drug Pumitamig (BNT327) and How Well it Works in 
 Patients With Recurrent Glioblastoma\nEstimated primary completion: Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729721
 2
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®
 \, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in
  Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal Can
 cer\nEstimated primary completion: 15 February 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947941-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 947941)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate Safety and Efficacy of KarXT + KarX-E
 C as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-
 5)\nEstimated primary completion: 21 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06947941
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03093116-2264@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT03093116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring AL
 K\, ROS1\, or NTRK1-3 Rearrangements\nEstimated primary completion: 29 Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrect
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03093116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070232-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07070232)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Test if an I
 nvestigational Treatment Called BNT326 is Safe and Potentially Beneficial 
 When Used Alone or in Combination With Other Investigational Treatments Su
 ch as BNT327\, for People With Advanced Malignant Tumors\nEstimated primar
 y completion: March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07070232
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926868-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT06926868)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3.\nStudy: A Study of Izalont
 amab Brengitecan Versus Chemotherapy in Participants With Previously Untre
 ated\, Locally Advanced\, Recurrent Inoperable\, or Metastatic Triple-nega
 tive Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)\n
 Estimated primary completion: 13 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06926868
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871214-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07871214)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Assess The Safety and Tolerability of Pumitamig-Based Therapy Admini
 stered Before Surgery in Participants With Early-Stage Non-Small Cell Lung
  Cancer (ROSETTA Lung-220)\nEstimated primary completion: 15 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07871214
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-11182@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06911502)
DESCRIPTION:Golcadomide\, phase 3.\nStudy: A Study to Compare the Efficacy 
 and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Inv
 estigator's Choice in Participants With Relapsed/Refractory Follicular Lym
 phoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK
 -4)\nEstimated primary completion: 24 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015983-11187@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280517
DTEND;VALUE=DATE:20280518
SUMMARY:Zolacabtagene autoleucel: Phase 2 readout est. (NCT07015983)
DESCRIPTION:Zolacabtagene autoleucel\, phase 2\, Systemic Lupus Erythematos
 us.\nStudy: A Study of CC-97540 (BMS-986353 or Zola-cel)\, CD19-Targeted N
 EX-T CAR T Cells\, in Participants With Active SLE Despite Immunosuppressa
 nts (Breakfree-SLE)\nEstimated primary completion: 17 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07015983
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 929273)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Assess the Long-term Safety of KarXT for the Trea
 tment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)\nEstimated primar
 y completion: 13 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160725-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07160725)
DESCRIPTION:Pumitamig\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase 
 1/2a\, First-in-human\, Study of BMS-986517 in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: 31 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07160725
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469737-11033@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Azacitidine (Onureg): Phase 2/3 readout est. (NCT05469737)
DESCRIPTION:Azacitidine (Onureg)\, phase 2/3.\nStudy: A Study to Compare th
 e Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) 
 Versus Placebo Plus BSC in Participants With International Prognostic Scor
 ing System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Synd
 rome (MDS)\nEstimated primary completion: 31 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05469737
URL:https://assetmemo.bio/drug/azacitidine-onureg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449222-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06449222)
DESCRIPTION:Pumitamig\, phase 2.\nStudy: Safety and Preliminary Effectivene
 ss of BNT327\, an Investigational Therapy for Breast Cancer\, When Given i
 n Combination With Chemotherapy\nEstimated primary completion: August 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06449222
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-1963@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study of Navlimetostat (BMS
 -986504) Monotherapy and in Combination With Other Agents in Participants 
 With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
  (MountainTAP-5)\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817007-3207@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ezobresib: Phase 1/2 readout est. (NCT04817007)
DESCRIPTION:Ezobresib\, phase 1/2.\nStudy: A Study to Assess the Safety and
  Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitin
 ib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)\nEstima
 ted primary completion: 31 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ezobresib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04817007
URL:https://assetmemo.bio/drug/ezobresib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892548-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06892548)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Investigate 
 the Efficacy and Safety of an Investigational Combination Therapy With BNT
 324 and BNT327 in Patients With Advanced Lung Cancer\nEstimated primary co
 mpletion: September 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06892548
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976203-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976203)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)\nEstimat
 ed primary completion: 11 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06976203
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976216-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 976216)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT + Ka
 rX-EC for Cognitive Impairment in Alzheimer's Disease\nEstimated primary c
 ompletion: 11 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06976216
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07680764)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy To Assess the Safety\, Tolerability\, and Efficacy of Imzokitug in Comb
 ination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pum
 itamig and PDCT as First-line Treatment for Participants With Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882785-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 882785)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT in Acutely
  Psychotic Japanese Adult Participants With Schizophrenia\nEstimated prima
 ry completion: 23 September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06882785
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590857-9190@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 1/2 readout est. (NCT06590857
 )
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 1/2\, HR+/HER2- Metastat
 ic Breast Cancer.\nStudy: Trial of 225Ac-DOTATATE (RYZ101) in Subjects Wit
 h ER+\, HER2-negative Unresectable or Metastatic Breast Cancer Expressing 
 SSTRs.\nEstimated primary completion: October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06590857
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841055-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06841055)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Preliminary Efficacy of Pumitamig (BNT327)\, an Investigational Ther
 apy for Patients With Non-small Cell Lung Cancer in Combination With Chemo
 therapy as First-line or Second-line Treatment\nEstimated primary completi
 on: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pum
 itamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06841055
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1963@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-9865
 23 Alone and in Combination With Anti-Cancer Agents in Participants With A
 dvanced Solid Malignancies\nEstimated primary completion: 13 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111520-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07111520)
DESCRIPTION:Pumitamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Trial to Test if an Investigational Combination Therapy With BNT32
 6 and BNT327 is Safe and Potentially Beneficial for People With Advanced N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07111520
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011745-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281103
DTEND;VALUE=DATE:20281104
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease\nEstimated primary completion: 3 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07011745
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772531-11181@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281106
DTEND;VALUE=DATE:20281107
SUMMARY:Evifacotrep: Phase 2 readout est. (NCT07772531)
DESCRIPTION:Evifacotrep\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy to Evaluate BMS-986511 in Adults With Major Depressive Disorder\nEstim
 ated primary completion: 6 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/evifacotrep#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07772531
URL:https://assetmemo.bio/drug/evifacotrep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-11187@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Zolacabtagene autoleucel: Phase 3 readout est. (NCT07335562)
DESCRIPTION:Zolacabtagene autoleucel\, phase 3.\nStudy: A Study to Compare 
 the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-ce
 l)\, CD19-CAR T Cells\, Versus Standard of Care in Participants With Activ
 e Systemic Sclerosis\nEstimated primary completion: 14 November 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zolacabtagene-autoleucel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 5562
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011732-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 011732)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Phase 3 Study to Evaluate the Safety and Efficacy of Ka
 rXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's D
 isease (ADAGIO-1)\nEstimated primary completion: 24 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 11732
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827261-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07827261)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 Combined With Glecirasib in Patients With KRA
 S G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07827261
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641855-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07641855)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3.\nStudy: A Study of BL-B01D
 1 Combination Therapy in Patients With Metastatic Castration-resistant Pro
 state Cancer\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07641855
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554456-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07554456)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Esophageal Squamous Cell 
 Carcinoma.\nStudy: A Study of BL-B01D1 in Combination With Tislelizumab ±
 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as Fir
 st-line Treatment in Patients With Unresectable\, Locally Advanced Recurre
 nt or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07554456
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838273-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06838273)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Versus Osimer
 tinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06838273
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582315-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07582315)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Pati
 ents With Locally Advanced or Metastatic Biliary Tract Cancer After Failur
 e of Platinum-based Chemotherapy(PANKU-BTC01)\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iza
 lontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07582315
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648914-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07648914)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Comparing BL-B01D1 With Chemotherapy of Physician
 's Choice in Patients With Unresectable Locally Advanced\, Recurrent\, or 
 Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therap
 y(PANKU-Breast03)\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07648914
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100080-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07100080)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-b
 ased Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small C
 ell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)\nEsti
 mated primary completion: 15 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07100080
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855771-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06855771)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of Navlimetostat (BMS-986504) Alone or in Combination Wit
 h Izalontamab Brengitecan in Participants With Pre-treated Advanced or Met
 astatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion o
 r MTAP Loss (MountainTAP-9)\nEstimated primary completion: 29 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06855771
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712316-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT06712316)
DESCRIPTION:Pumitamig\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety\, Efficacy\, and Pharmacokinetics of BNT327 in Combination With Chemot
 herapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)\
 nEstimated primary completion: January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06712316
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772079-100@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT04772079)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Drug Levels\, Efficacy and Safety of Deucravacitinib in 
 Children and Adolescent Participants With Moderate to Severe Plaque Psoria
 sis\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04772079
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697197-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06697197)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study of BMS-986482 Alone or a
 s Combination Therapy in Participants With Advanced Solid Tumors\nEstimate
 d primary completion: 4 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06697197
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106762-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07106762)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Urothelial Carcinoma.\nSt
 udy: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemothe
 rapy for Metastatic Urothelial Cancer With Disease Progression on or After
  Immunotherapy\nEstimated primary completion: 26 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07106762
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622941-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06622941)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study to ONO-4538 in Patients With
  Rhabdoid Tumor\nEstimated primary completion: 31 January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06622941
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686263-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 686263)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: Relapse Prevention Trial Evaluating KarXT Treatment in Schizoph
 renia\nEstimated primary completion: 3 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07686263
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827016-3209@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05827016)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: A S
 tudy to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance The
 rapy Following Autologous Stem Cell Transplant in Participants With Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 15 March 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05827016
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712355-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pumitamig: Phase 3 readout est. (NCT06712355)
DESCRIPTION:Pumitamig\, phase 3\, Small Cell Lung Cancer.\nStudy: Safety an
 d Efficacy of BNT327\, an Investigational Therapy in Combination With Chem
 otherapy for Patients With Untreated Small-cell Lung Cancer\nEstimated pri
 mary completion: April 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06712355
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325136-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07325136)
DESCRIPTION:Pumitamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study
  to Assess the Safety and Tolerability of BMS-986525 Alone and in Combinat
 ion Therapy in Participants With Relapsed/Refractory Small Cell Lung Cance
 r\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07325136
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076121-2283@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290503
DTEND;VALUE=DATE:20290504
SUMMARY:Navlimetostat: Phase 2/3 readout est. (NCT07076121)
DESCRIPTION:Navlimetostat\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\n
 Study: A Study Comparing Navlimetostat (BMS-986504) in Combination With Na
 b-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclit
 axel and Gemcitabine in Participants With Untreated Metastatic Pancreatic 
 Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)\nEsti
 mated primary completion: 3 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/navlimetostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07076121
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937229-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 937229)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Alzheimer's 
 Disease.\nStudy: A Study to Evaluate the Long-term Efficacy and Safety of 
 KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)\nEstimated
  primary completion: 22 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06937229
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940777-660@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290721
DTEND;VALUE=DATE:20290722
SUMMARY:Camzyos (Mavacamten): Phase 3 readout est. (NCT07940777)
DESCRIPTION:Camzyos (Mavacamten)\, phase 3\, Hypertrophic Cardiomyopathy.\n
 Study: A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults
  With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HC
 M)\nEstimated primary completion: 21 July 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/mavacamten#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07940777
URL:https://assetmemo.bio/drug/mavacamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936943-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06936943)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Study in Patients With Ri
 chter's Transformation\nEstimated primary completion: 31 July 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06936943
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827236-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT06827236)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Find the Opt
 imal Dose of an Investigational Treatment Called BNT323 When Used in Combi
 nation With Another Investigational Treatment\, BNT327\, and to Test if Th
 at Combination Treatment is Safe and Beneficial for Patients With Advanced
  Breast Cancer\nEstimated primary completion: August 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06827236
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284745-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 284745)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism\nEstimated primary completion: 6 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072847
 45
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285798-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290806
DTEND;VALUE=DATE:20290807
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 285798)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3.\nStudy: A Stu
 dy of KarXT + KarX-EC for Treatment of Irritability in Children and Adoles
 cents With Autism Spectrum Disorder\nEstimated primary completion: 6 Augus
 t 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-tr
 ospium-chloride#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07285798
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimate
 d primary completion: 25 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979453-100@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291012
DTEND;VALUE=DATE:20291013
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06979453)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Efficacy\, Safety\, and Drug Levels of Deucravacitinib (
 BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psor
 iasis\nEstimated primary completion: 12 October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06979453
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291076-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07291076)
DESCRIPTION:Pumitamig\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A Stu
 dy to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combin
 ation With Ipilimumab in Participants With First-Line Advanced or Unresect
 able Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)\nEstimated primary c
 ompletion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07291076
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Pumitamig\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Study t
 o Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone or 
 in Combination With Other Agents in Participants With Advanced Renal Cell 
 Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072933
 51
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739186-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739186)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bis
 pecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as
  First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-
 small Cell Lung Cancer(PANKU-Lung06)\nEstimated primary completion: Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-
 brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07739186
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739199-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739199)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispec
 ific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific
  Antibody in First-line Patients With Locally Advanced or Metastatic Squam
 ous Non-small Cell Lung Cancer(PANKU-Lung05)\nEstimated primary completion
 : December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07739199
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173751-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07173751)
DESCRIPTION:Pumitamig\, phase 3.\nStudy: ROSETTA Breast-01: The Effects and
  Safety of Pumitamig in Patients With Triple-Negative Breast Cancer\nEstim
 ated primary completion: December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07173751
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502300-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07502300)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study Comparing BL
 -B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy 
 Combined With Tislelizumab as First-line Treatment in Patients With Extens
 ive-stage Small Cell Lung Cancer(PANKU-Lung07)\nEstimated primary completi
 on: December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iz
 alontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07502300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729956-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07729956)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study of BL-B01D1 
 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibod
 y in Patients With Previously Untreated\, Locally Advanced\, Inoperable or
  Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANK
 U-Breast04)\nEstimated primary completion: December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07729956
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288567-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 288567)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT for the Tr
 eatment of Schizophrenia in Adolescents (EMERGENT TEEN)\nEstimated primary
  completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07288567
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939815-11191@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291229
DTEND;VALUE=DATE:20291230
SUMMARY:BMS-986548: Phase 1/2 readout est. (NCT07939815)
DESCRIPTION:BMS-986548\, phase 1/2.\nStudy: A Study of BMS-986548 as Monoth
 erapy and in Combination With Anti-cancer Agents in Participants With Adva
 nced Solid Malignancies\nEstimated primary completion: 29 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bms-986548#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07939815
URL:https://assetmemo.bio/drug/bms-986548#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221357-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300202
DTEND;VALUE=DATE:20300203
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT07221357)
DESCRIPTION:Pumitamig\, phase 2/3.\nStudy: A Study to Evaluate the Safety a
 nd Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizum
 ab in Combination With Chemotherapy in Participants With Previously Untrea
 ted\, Unresectable\, or Metastatic Colorectal Cancer\nEstimated primary co
 mpletion: 2 February 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07221357
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869551-100@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300306
DTEND;VALUE=DATE:20300307
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06869551)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: A Study to Evaluate the Drug Levels\, Efficacy\, and Safety of Deucrav
 acitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Ar
 thritis\nEstimated primary completion: 6 March 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06869551
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424404-712@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 424404)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Long-term Safety and Tolerability of Xa
 nomeline and Trospium Chloride for the Treatment of Psychiatric Disorders 
 in Children and Adolescents\nEstimated primary completion: 8 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-ch
 loride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07424404
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881120-5538@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Afimetoran: Phase 2/3 readout est. (NCT07881120)
DESCRIPTION:Afimetoran\, phase 2/3.\nStudy: Study of Afimetoran in Adults W
 ith Cutaneous Lupus Erythematosus\nEstimated primary completion: April 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/afimetoran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07881120
URL:https://assetmemo.bio/drug/afimetoran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603557-11187@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300506
DTEND;VALUE=DATE:20300507
SUMMARY:Zolacabtagene autoleucel: Phase 2 readout est. (NCT07603557)
DESCRIPTION:Zolacabtagene autoleucel\, phase 2.\nStudy: Study of Zola-cel (
 BMS-986353)\, in Participants With Autoimmune Cytopenia (Breakfree-AiCE)\n
 Estimated primary completion: 6 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07603557
URL:https://assetmemo.bio/drug/zolacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726161-11185@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:RYZ801: Phase 1/2 readout est. (NCT06726161)
DESCRIPTION:RYZ801\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Study of
  the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Iden
 tify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC\nEstimate
 d primary completion: June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ryz801#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06726161
URL:https://assetmemo.bio/drug/ryz801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy v
 s Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-
 small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary com
 pletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06561386
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361497-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300918
DTEND;VALUE=DATE:20300919
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361497)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradia
 tion Therapy in Participants With Unresectable Stage III Non-small Cell Lu
 ng Cancer (NSCLC) (ROSETTA Lung-201)\nEstimated primary completion: 18 Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 361497
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221149-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301108
DTEND;VALUE=DATE:20301109
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT07221149)
DESCRIPTION:Pumitamig\, phase 2/3.\nStudy: A Study to Evaluate the Safety a
 nd Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab
  in Combination With Chemotherapy in Participants With Previously Untreate
 d Advanced or Metastatic Gastric\, Gastroesophageal Junction\, or Esophage
 al Adenocarcinoma (ROSETTA Gastric-204)\nEstimated primary completion: 8 N
 ovember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitam
 ig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7221149
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079631-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07079631)
DESCRIPTION:Pumitamig\, phase 1/2.\nStudy: A Clinical Study to Test if an I
 nvestigational Treatment Called BNT314 When Used in Combination With Anoth
 er Investigational Treatment Pumitamig (BNT327) and Chemotherapy\, is Bene
 ficial and Safe for Patients With Advanced Colorectal Cancer\nEstimated pr
 imary completion: December 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07079631
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797881-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07797881)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Nasopharyngeal Carcinoma.\n
 Study: A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Pat
 ients With High-Risk Locally Advanced Nasopharyngeal Carcinoma\nEstimated 
 primary completion: December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07797881
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640789-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07640789)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 in Combination With Osimertinib Versus
  Osimertinib Alone in Patients With Locally Advanced\, Unresectable EGFR-m
 utated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progres
 sed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung0
 8)\nEstimated primary completion: December 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07640789
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116967-100@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310116
DTEND;VALUE=DATE:20310117
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07116967)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: Long-T
 erm Safety Study of Deucravacitinib Versus Ustekinumab in Participants Wit
 h Psoriasis (PRAGMATYK)\nEstimated primary completion: 16 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07116967
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Nivolumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Evaluate the Safety\, Tolerability\, Drug Levels\, and Pre
 liminary Efficacy of BMS-986507 Combinations in Adult Participants With Ad
 vanced Solid Tumors\nEstimated primary completion: 26 February 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408259-14@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Zeposia (ozanimod): Phase 3 readout est. (NCT06408259)
DESCRIPTION:Zeposia (ozanimod)\, phase 3\, Multiple Sclerosis.\nStudy: Stud
 y to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingoli
 mod in Children and Adolescents With Relapsing Remitting Multiple Sclerosi
 s\nEstimated primary completion: 11 April 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ozanimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06408259
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-1963@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pe
 mbrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemoth
 erapy in First-line Metastatic Non-small Cell Lung Cancer Participants Wit
 h Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361510-1990@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361510)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participa
 nts With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L
 1 ≥ 50%. (ROSETTA Lung-202)\nEstimated primary completion: 14 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07361510
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680790-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07680790)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Izalontamab Brengitecan (BMS-986507) in Combination With
  Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination 
 With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZ
 ABRIGHT-Lung02)\nEstimated primary completion: 30 December 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07680790
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076175-14@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20320712
DTEND;VALUE=DATE:20320713
SUMMARY:Zeposia (ozanimod): Phase 2/3 readout est. (NCT05076175)
DESCRIPTION:Zeposia (ozanimod)\, phase 2/3\, Ulcerative Colitis.\nStudy: A 
 Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With
  Moderate to Severe Active Ulcerative Colitis\nEstimated primary completio
 n: 12 July 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ozan
 imod#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05076175
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771465-596@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Danicamtiv: Phase 3 readout est. (NCT07771465)
DESCRIPTION:Danicamtiv\, phase 3.\nStudy: A Study of the Long-term Safety a
 nd Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial 
 Dilated Cardiomyopathy\nEstimated primary completion: November 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07771465
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642024-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07642024)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-B01D1 in Combination With Osimertinib as Perioper
 ative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung
  Cancer(PANKU-Lung09)\nEstimated primary completion: December 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764202
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783321-2044@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07783321)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenan
 ce Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-li
 ne Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NP
 C02)\nEstimated primary completion: December 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07783321
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
